Linda Chang joins PharmAthene as CFO
This article was originally published in Scrip
Executive Summary
PharmAthene, a company developing and commercialising medical countermeasures against biological and chemical weapons, has appointed Linda Chang senior vice-president and chief financial officer. Prior to joining PharmAthene Ms Chang was senior director of finance at Human Genome Sciences.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.